QZaffre/Haleon_Cloud · Datasets at Hugging Face

text stringlengths 0 1.36k
sj-docx-3-tar-10.1177_17534666241228927 – Supplemental material for A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold:
Click here to view.(30K, docx)
Supplemental material, sj-docx-3-tar-10.1177_17534666241228927 for A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold by Martina Hagen, Kim Clark, Pranab Kalita, Gessica Serra, Edwin Sanchez, Gabor Varbiro and Mathieu M. Albasser in Therapeutic Advances in Respiratory Disease

sj-tif-2-tar-10.1177_17534666241228927 – Supplemental material for A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold:
Click here to view.(569K, tif)
Supplemental material, sj-tif-2-tar-10.1177_17534666241228927 for A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold by Martina Hagen, Kim Clark, Pranab Kalita, Gessica Serra, Edwin Sanchez, Gabor Varbiro and Mathieu M. Albasser in Therapeutic Advances in Respiratory Disease

Go to:
Acknowledgments
The authors would like to thank all participants and everyone involved in conducting the studies and analyzing the data. The authors would like to thank Yoshita Anandarajah and Mizpah Lamptey for their contributions during study design, study execution, and reporting of data. Medical writing assistance was provided by Sandra Malagon and Shuang Song of Nucleus Global, UK, which was funded by Haleon in accordance with Good Publication Practice (GPP2022) guidelines.

Go to:
Footnotes
ORCID iD: Martina Hagen An external file that holds a picture, illustration, etc.
Object name is 10.1177_17534666241228927-img1.jpg https://orcid.org/0009-0004-9542-630X

Supplemental material: Supplemental material for this article is available online.

Go to:
Contributor Information
Martina Hagen, Haleon CH SARL, Route de l’Etraz 2, Nyon 1279, 1260, Switzerland.

Kim Clark, Haleon, Weybridge, Surrey, UK.

Pranab Kalita, Haleon, Weybridge, Surrey, UK.

Gessica Serra, Haleon, Weybridge, Surrey, UK.

Edwin Sanchez, Haleon, Warren, NJ, USA.

Gabor Varbiro, Haleon, Weybridge, Surrey, UK.

Mathieu M. Albasser, Haleon CH SARL, Nyon, Switzerland.

Go to:
Declarations
Ethics approval and consent to participate: This study was conducted in compliance with the protocol and in accordance with Good Clinical Practices Medicines and Healthcare products Regulatory Agency regulations, and all applicable local and state regulations. Signature of the eIC was required and obtained from all participants before any study-related activities. The eIC was reviewed by West Midlands, Edgbaston, Research Ethics Committee, Manchester, UK. IRAS project ID 1006069, REC:22/WM/0177. Approved by West Midlands – Edgbaston Research Ethics Committee 25 October 2022.

Consent for publication: Consent for publication was provided by participants through the eIC form.

Contributed by
Author contributions: Martina Hagen: Conceptualization; Formal analysis; Writing – review & editing.

Kim Clark: Methodology; Writing – review & editing.
Pranab Kalita: Conceptualization; Writing – review & editing.

Gessica Serra: Methodology; Writing – review & editing.

Edwin Sanchez: Formal analysis; Writing – review & editing.

Gabor Varbiro: Formal analysis; Methodology; Writing – review & editing.

Mathieu M. Albasser: Formal analysis; Writing – review & editing.

Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Haleon.

Competing interests: All authors are employees of Haleon.

Availability of data and materials: Anonymized individual participant data and study documents can be requested for further research from https://haleon-study-register.idea-point.com. Clinical trial details can be found on Study Record \| Beta ClinicalTrials.gov.

Go to:
References

sj-docx-3-tar-10.1177_17534666241228927 – Supplemental material for A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold:

Click here to view.(30K, docx)

Supplemental material, sj-docx-3-tar-10.1177_17534666241228927 for A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold by Martina Hagen, Kim Clark, Pranab Kalita, Gessica Serra, Edwin Sanchez, Gabor Varbiro and Mathieu M. Albasser in Therapeutic Advances in Respiratory Disease

sj-tif-2-tar-10.1177_17534666241228927 – Supplemental material for A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold:

Click here to view.(569K, tif)

Supplemental material, sj-tif-2-tar-10.1177_17534666241228927 for A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold by Martina Hagen, Kim Clark, Pranab Kalita, Gessica Serra, Edwin Sanchez, Gabor Varbiro and Mathieu M. Albasser in Therapeutic Advances in Respiratory Disease

Go to:

Acknowledgments

The authors would like to thank all participants and everyone involved in conducting the studies and analyzing the data. The authors would like to thank Yoshita Anandarajah and Mizpah Lamptey for their contributions during study design, study execution, and reporting of data. Medical writing assistance was provided by Sandra Malagon and Shuang Song of Nucleus Global, UK, which was funded by Haleon in accordance with Good Publication Practice (GPP2022) guidelines.

Go to:

Footnotes

ORCID iD: Martina Hagen An external file that holds a picture, illustration, etc.

Object name is 10.1177_17534666241228927-img1.jpg https://orcid.org/0009-0004-9542-630X

Supplemental material: Supplemental material for this article is available online.

Go to:

Contributor Information

Martina Hagen, Haleon CH SARL, Route de l’Etraz 2, Nyon 1279, 1260, Switzerland.

Kim Clark, Haleon, Weybridge, Surrey, UK.

Pranab Kalita, Haleon, Weybridge, Surrey, UK.

Gessica Serra, Haleon, Weybridge, Surrey, UK.

Edwin Sanchez, Haleon, Warren, NJ, USA.

Gabor Varbiro, Haleon, Weybridge, Surrey, UK.

Mathieu M. Albasser, Haleon CH SARL, Nyon, Switzerland.

Go to:

Declarations

Ethics approval and consent to participate: This study was conducted in compliance with the protocol and in accordance with Good Clinical Practices Medicines and Healthcare products Regulatory Agency regulations, and all applicable local and state regulations. Signature of the eIC was required and obtained from all participants before any study-related activities. The eIC was reviewed by West Midlands, Edgbaston, Research Ethics Committee, Manchester, UK. IRAS project ID 1006069, REC:22/WM/0177. Approved by West Midlands – Edgbaston Research Ethics Committee 25 October 2022.

Consent for publication: Consent for publication was provided by participants through the eIC form.

Contributed by

Author contributions: Martina Hagen: Conceptualization; Formal analysis; Writing – review & editing.

Kim Clark: Methodology; Writing – review & editing.

Pranab Kalita: Conceptualization; Writing – review & editing.

Gessica Serra: Methodology; Writing – review & editing.

Edwin Sanchez: Formal analysis; Writing – review & editing.

Gabor Varbiro: Formal analysis; Methodology; Writing – review & editing.

Mathieu M. Albasser: Formal analysis; Writing – review & editing.

Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Haleon.

Competing interests: All authors are employees of Haleon.

Availability of data and materials: Anonymized individual participant data and study documents can be requested for further research from https://haleon-study-register.idea-point.com. Clinical trial details can be found on Study Record | Beta ClinicalTrials.gov.

Go to:

References